COMPANIES
Resources
Blog
Margaret McCartney‘s blog
Walk while you work: Bosses are being nudged to make workplaces “healthier”. But moving the photocopier to make people walk more hardly seems sensible
Multimedia
View from the Top
Peter Schoenfeld of PSAM talks about the Paulson plan and why he wants to see the US ban on short-selling lifted
Principal content
Philips struck by fall in consumer confidence
The Dutch electronics group plans to introduce cost-cutting initiatives as the global financial crisis takes effect and the company sees demand dropping
Fears over the health of UK life sector
The Financial Services Authority is concerned over the strength of the life assurance industry despite tighter regulation being enforced since the last bear market in 2004
Doctors shortage imperils healthcare pledge
Inadequate supply of primary care physicians and certain specialists in Massachusetts threatens the state’s reform initiative and could hinder efforts to enact universal healthcare
Japanese drug group buys rival for $2bn
Mediceo Paltac, Japan’s largest pharmaceuticals wholesaler, is to buy its biggest domestic rival in a $2bn deal designed to combat falling drug prices
Proposed controls threaten EU drug trade
Distributors who arbitrage the price differences across Europe could see their $5.5bn a year trade severely curtailed under new rules and legislation set to be unveiled by Brussels
Drug groups urged to cut NHS prices
The government is pushing pharmaceutical companies to offer lower prices for new drugs on the understanding that the NHS will pay more if later evidence proves greater effectiveness
Epistem hurt by cell research costs
Demand for contract pharmaceutical research helped boost revenues by 50 per cent to £2.1m at Epistem, the biotechnology group
Lex: Eli Lilly buys ImClone
Biotechnology stocks once underperformed the broader Nasdaq but have found favour as banks, brokers and insurance companies redefine a risky bet
ImClone backs $6.5bn Eli Lilly bid
The US cancer drug maker agrees a $70 a share cash offer from Eli Lilly, which trumped an unsolicited approach from ImClone’s partner Bristol-Myers Squibb
United Drug eyes double-digit growth despite difficulties
United Drug, the wholesaler of pharmaceuticals and medical equipment, is poised to report double-digit earnings growth this year
Related content and features
Business Life
Medicine for a sector
As global pressures mount, French pharmaceutical companies are looking further afield for solutions to their problems
LEX
ImClone/Eli Lilly
The biotech company chaired by Carl Icahn says an unidentified party had completed due diligence, with negotiations under way
Eli Lilly buys ImClone
While markets around the world panicked, Eli Lilly announced an agreement to pay $6.5bn for ImClone – a market value double that of June, before speculation of a buyer arose
Track this Topic
News alerts
Email - create a keyword alert on the subject of this topic
Email summaries
Email - start your day with daily email briefing on this topic
RSS feeds
RSS - Track this news topic using our feeds
Recent drugs and healthcare reports
Market research reports
| Report name | Author | Publish date | Cost |
|---|---|---|---|
| 2009 U.S. Pharmaceutical Preparation Mfg. Industry Report | Barnes Reports | 10/5/2008 | $149 |
| 2009 U.S. Offices of Dentists Industry Report | Barnes Reports | 10/5/2008 | $149 |
| 2009 U.S. Pharmacies & Drug Stores Industry Report | Barnes Reports | 10/5/2008 | $149 |
| Global Pharmaceutical Market Forecast to 2012 | RNCOS | 10/1/2008 | $1800 |
| HIV: Markets for Diagnostics and Therapeutics | Kalorama Information | 10/1/2008 | $3500 |
CLASSIFIED